Dechra Pharmaceuticals PLC
LSE:DPH
Intrinsic Value
Dechra Pharmaceuticals PLC is a holding company, which engages in the veterinary pharmaceuticals and related products business. [ Read More ]
The intrinsic value of one
DPH
stock under the Base Case scenario is
57.17
GBX.
Compared to the current market price of 3 866 GBX,
Dechra Pharmaceuticals PLC
is
Overvalued by 99%.
DPH's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
DPH or that its price is influenced by factors unrelated to fundamentals.
Dechra Pharmaceuticals PLC's market capitalization is 440.4B GBX.
DPH stock price is 3 866 GBX.
DPH stock (57.17 GBX) is 99% less than its price (3866 GBX).
DPH stock (100.17 GBX) is 97% less than its price (3866 GBX). Open Relative Valuation
DPH has positive Operating Income for the last twelve months.
DPH's Revenue has grown by 12% over the past 12 months.
DPH's ROIC (Return on Invested Capital) has decreased in the last 3 years from 6% to 2%.
DPH has positive Free Cash Flow for the last twelve months.
DPH's Revenue is forecast to grow at a rate of 9% per year over the next 3 years.
DPH has negative Net Income for the last twelve months.
DPH's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 2%.
DPH has positive three-year average ROE (Return on Equity): 6%. The company is efficient at transforming stockholders' equity into net income.
DPH has positive three-year average ROIC (Return on Invested Capital): 6%. The company is efficient at using invested capital to generate operating income.
DPH's Revenue has been growing by 14% per year for the last 3 years.
DPH's ROE (Return on Equity) has significantly decreased in the last 3 years from 8% to -4%.
DPH's ROE (Return on Equity) for the past 12 months is negative and is equal to -4%.
DPH's long-term assets (2B GBP) exceed its long-term liabilties (814m GBP).
DPH's D/E (Debt to Equity) is very low and is equal to 0.66.
DPH has positive Gross Profit for the last twelve months.
DPH's short-term assets (468m GBP) exceed its short-term liabilties (164m GBP).
DPH has positive Net Debt. This means that the company has more debt (501m GBP) than cash and short-term investments (74m GBP).
DPH's Altman Z-Score is very high and is equal to 310.27.
DPH generates enough operating income (25m GBP) to cover interest payments on its debt (18m GBP).
Valuation Backtest
Dechra Pharmaceuticals PLC
Run backtest to discover the historical profit from buying and selling
DPH
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Dechra Pharmaceuticals PLC
Balance Sheet Decomposition
Dechra Pharmaceuticals PLC
| Current Assets | 467.9m |
| Cash & Short-Term Investments | 74.4m |
| Receivables | 176.2m |
| Other Current Assets | 217.3m |
| Non-Current Assets | 1.1B |
| Long-Term Investments | 14.9m |
| PP&E | 159.3m |
| Intangibles | 922.4m |
| Other Non-Current Assets | 4.9m |
| Current Liabilities | 164m |
| Accounts Payable | 144.5m |
| Other Current Liabilities | 19.5m |
| Non-Current Liabilities | 650.2m |
| Long-Term Debt | 500.6m |
| Other Non-Current Liabilities | 149.6m |
Earnings Waterfall
Dechra Pharmaceuticals PLC
|
Revenue
|
761.5m
GBP
|
|
Cost of Revenue
|
-331.9m
GBP
|
|
Gross Profit
|
429.6m
GBP
|
|
Operating Expenses
|
-404.7m
GBP
|
|
Operating Income
|
24.9m
GBP
|
|
Other Expenses
|
-52.8m
GBP
|
|
Net Income
|
-27.9m
GBP
|
Free Cash Flow Analysis
Dechra Pharmaceuticals PLC
DPH Profitability Score
Profitability Due Diligence
Dechra Pharmaceuticals PLC's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Dechra Pharmaceuticals PLC's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
DPH Solvency Score
Solvency Due Diligence
Dechra Pharmaceuticals PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Dechra Pharmaceuticals PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DPH Price Targets Summary
Dechra Pharmaceuticals PLC
According to Wall Street analysts, the average 1-year price target for
DPH
is 4 189 GBX
.
Shareholder Return
DPH Price
Dechra Pharmaceuticals PLC
| Average Annual Return | 6.69% |
| Standard Deviation of Annual Returns | 36.29% |
| Max Drawdown | -53% |
| Market Capitalization | 440.4B GBX |
| Shares Outstanding | 11 390 610 450 |
| Percentage of Shares Shorted | 89% |
Company Profile
Dechra Pharmaceuticals PLC
Country
Industry
Market Cap
Dividend Yield
Description
Dechra Pharmaceuticals PLC is a holding company, which engages in the veterinary pharmaceuticals and related products business. The company is headquartered in Northwich, Cheshire and currently employs 1,945 full-time employees. The company went IPO on 2000-09-21. The firm is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Dechra Veterinary Products International and Dechra Pharmaceuticals Manufacturing. The company manufactures and markets companion animal, equine, food producing animal products and nutrition. The North American (NA) Pharmaceuticals segment consists of Dechra Veterinary Products US, Dechra Produtas Veterinarios (Mexico) and Dechra Veterinary Products Canada, which sells companion animal, equine and food producing animal products. The segment also includes its manufacturing units based in Melbourne, Florida and Fort Worth, Texas.
Contact
IPO
Employees
Officers
The intrinsic value of one
DPH
stock under the Base Case scenario is
57.17
GBX.
Compared to the current market price of 3 866 GBX,
Dechra Pharmaceuticals PLC
is
Overvalued by 99%.
You don't have any saved screeners yet
